New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareCortagen vs Liraglutide

Cortagen vs Liraglutide

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & LongevityRecovery & Repair
Cortagen
GLP-1 / Weight Loss AgonistsFat Loss & Metabolic
Liraglutide
Summary
Cortagen is a synthetic tetrapeptide (Ala-Glu-Asp-Pro) developed at the St. Petersburg Institute of Bioregulation as a cardioprotective and vascular bioregulator. It stimulates repair of cardiac and vascular tissue, with demonstrated benefits for coronary artery disease, atherosclerosis, and cardiac aging.
Liraglutide is a long-acting GLP-1 receptor agonist approved for type 2 diabetes (Victoza) and chronic weight management (Saxenda). It reduces appetite, slows gastric emptying, improves insulin secretion, and promotes weight loss of 5–10% in clinical trials.
Half-Life
Short peptide half-life; gene regulatory effects persist beyond peptide clearance
~13 hours (once-daily dosing)
Admin Route
SubQ, IM, Oral
SubQ
Research
Typical Dose
10 mg SC or IM daily
Start 0.6 mg, titrate to 3 mg
Frequency
Once daily
Once daily
Key Benefits
  • Cardioprotective — protects cardiac tissue from ischemic damage
  • Promotes cardiac regeneration and repair
  • Improves vascular endothelium function
  • Reduces atherosclerosis progression
  • Anti-aging effect on heart muscle cells
  • Improves cardiac output and exercise capacity
  • Reduces oxidative stress in cardiovascular tissue
  • May reduce arrhythmia frequency
  • Promotes weight loss (5–10% average)
  • Reduces appetite and caloric intake
  • Improves blood glucose control (HbA1c reduction)
  • Reduces cardiovascular events in T2DM (LEADER trial)
  • Slows gastric emptying
  • FDA-approved for T2DM and chronic weight management
  • Cardioprotective effects shown in clinical trials
  • May improve fatty liver (NAFLD/NASH)
Side Effects
  • Excellent safety profile
  • Mild injection site reactions
  • Rare: transient hypotension
  • Rare: mild arrhythmia at initiation in cardiac patients
  • Nausea (very common, especially initially)
  • Vomiting
  • Diarrhea or constipation
  • Decreased appetite
  • +5 more
Stacks With